Browse by Phase
Phase 2 Clinical Trials
Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.
Total Trials
1,083
Recruiting Now
1,083
Top Conditions in Phase 2
Frequently Asked Questions — Phase 2 Trials
What does a Phase 2 clinical trial evaluate?
Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.
How long do Phase 2 trials typically take?
Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.
Who can participate in a Phase 2 clinical trial?
Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.
Active Phase 2 Studies
NCT04214366 Phase 2
Recruiting
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Condition
Adenoid Cystic Carcinoma
Enrollment
314 pts
Location
Germany
Sponsor
Heidelberg University
NCT06882174 Phase 2
Recruiting
This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrol...
Condition
Metastatic Non Small Cell Lung Cancer
Enrollment
58 pts
Location
Canada
Sponsor
AHS Cancer Control Alberta
NCT07003542 Phase 2
Recruiting
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive ...
Condition
Glioblastoma
Enrollment
48 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent
NCT07536269 Phase 2
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in P...
Condition
Congenital Adrenal Hyperplasia
Enrollment
20 pts
Location
United States
Sponsor
Neurocrine Switzerland GmbH
NCT06736483 Phase 2
Recruiting
Intravenous Dexmedetomidine as an Adjuvant to Locoregional Anesthesia in Pediatr...
Condition
Anesthesia
Enrollment
200 pts
Location
France
Sponsor
University Hospital, Montpelli
NCT07369089 Phase 2
Recruiting
Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Re...
Condition
Opioid Use Disorder
Enrollment
88 pts
Location
United States
Sponsor
University of California, San
NCT07025824 Phase 2
Recruiting
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patie...
Condition
AML - Acute Myeloid Leukemia
Enrollment
220 pts
Location
Germany
Sponsor
Technische Universität Dresden
NCT06092086 Phase 2
Recruiting
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Condition
ALK Positive Non-small Cell Lung Cancer
Enrollment
126 pts
Location
China
Sponsor
Guangdong Association of Clini
NCT07005570 Phase 2
Recruiting
Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD...
Condition
pMMR/MSS Locally Advanced Rectal Cancer
Enrollment
86 pts
Location
China
Sponsor
Dechang Diao
NCT06130059 Phase 2
Recruiting
Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and ...
Condition
Heart Failure
Enrollment
60 pts
Location
United States
Sponsor
University of Texas Southweste
NCT06856603 Phase 2
Recruiting
OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6...
Condition
Metastatic Disease
Enrollment
50 pts
Location
Russia
Sponsor
National Medical Research Radi
NCT06639061 Phase 2
Recruiting
Neuromodulation of the Hippocampus to Reduce Intrusive Re-Experiencing in PTSD: ...
Condition
PTSD - Post Traumatic Stress Disorder
Enrollment
60 pts
Location
Israel
Sponsor
Tel Aviv University
NCT07437586 Phase 2
Recruiting
Topical GHK-Cu Gel for Acute Skin Wound Healing
Condition
Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)
Enrollment
60 pts
Location
China
Sponsor
Hudson Biotech
NCT07588568 Phase 2
Recruiting
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
Condition
EoE
Enrollment
52 pts
Location
United States
Sponsor
University of North Carolina,
NCT06447090 Phase 2
Recruiting
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Condition
Relapse Acute Myeloid Leukemia
Enrollment
30 pts
Location
China
Sponsor
Institute of Hematology & Bloo
NCT05955313 Phase 2
Recruiting
Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvody...
Condition
Vulvodynia
Enrollment
300 pts
Location
Poland
Sponsor
Medical University of Lublin
NCT06302491 Phase 2
Recruiting
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Condition
β -Thalassemia
Enrollment
64 pts
Location
China
Sponsor
Kind Pharmaceuticals LLC
NCT07847710 Phase 2
Recruiting
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plu...
Condition
Intrahepatic Cholangiocarcinoma (Icc)
Enrollment
81 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT03945162 Phase 2
Recruiting
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Mus...
Condition
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Enrollment
90 pts
Location
United States, Canada
Sponsor
Theralase® Technologies Inc.
NCT06761846 Phase 2
Recruiting
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and...
Condition
Gastric Adenocarcinoma
Enrollment
70 pts
Location
China
Sponsor
Cancer Institute and Hospital,
NCT06939088 Phase 2
Recruiting
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophreni...
Condition
Alcohol Use Disorder
Enrollment
108 pts
Location
Denmark
Sponsor
Anders Fink-Jensen, MD, DMSci
NCT07077746 Phase 2
Recruiting
HB-adMSCs for the Treatment of Crohn's Disease
Condition
Crohn Disease (CD)
Enrollment
46 pts
Location
United States
Sponsor
Hope Biosciences Research Foun
NCT07130786 Phase 2
Recruiting
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients ...
Condition
Seizures
Enrollment
150 pts
Location
United States
Sponsor
Ayal A. Aizer, MD
NCT07695597 Phase 2
Recruiting
A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
Condition
Mixed Hyperlipidemia
Enrollment
240 pts
Location
China
Sponsor
CSPC Zhongnuo Pharmaceutical (
NCT05755113 Phase 2
Recruiting
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate i...
Condition
Soft Tissue Sarcoma
Enrollment
40 pts
Location
United States
Sponsor
QBiotics Group Limited
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology